Literature DB >> 1620135

Machado-Joseph disease: an autosomal dominant motor system degeneration.

R N Rosenberg1.   

Abstract

Machado-Joseph disease is an autosomal dominant spinocerebellar degeneration. It expresses itself clinically with variable expression. Type one patients have early onset with a rapid progression of symptoms including spasticity, rigidity and myokymia. Type two patients are the most common phenotype with ataxia and spasticity. Type three patients develop progressive ataxia with variable amyotrophy. All patients have ophthalmoparesis and normal mental status. The neuropathology consists of neuronal loss and gliosis in the substantia nigra, motor cranial nuclei, dentate nucleus of the cerebellum, and variable neuronal loss with gliosis in the cerebellar cortex and neostriatum. The cerebral cortex is normal histologically. The inferior olivary nuclei are normal, thus separating this disease from olivopontocerebellar atrophy (OPCA). The disease has a worldwide distribution including families described in Portugal, the Azores, Spain, Italy, United States, Canada, Brazil, China, Taiwan, and Japan. The gene has not been mapped for this disease but the locus on chromosome 6p mapped for most families with OPCA has been excluded for this disorder.

Entities:  

Mesh:

Year:  1992        PMID: 1620135     DOI: 10.1002/mds.870070302

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  39 in total

1.  Clinical and genetic study of a family with spinocerebellar ataxia type 1 (SCA1) and beta-thalassemia.

Authors:  V Pietrini; M Godani; S Calzetti; A Negrotti; B Castellotti; M C Riggio; C Toffoli
Journal:  Ital J Neurol Sci       Date:  1998-12

Review 2.  Metabolic profiles to define the genome: can we hear the phenotypes?

Authors:  Julian L Griffin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-06-29       Impact factor: 6.237

Review 3.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

4.  Pearls & Oy-sters: Spinocerebellar ataxia type 3 presenting with cervical dystonia without ataxia.

Authors:  Jihad A Muglan; Suresh Menon; Mandar S Jog
Journal:  Neurology       Date:  2016-01-05       Impact factor: 9.910

5.  A familial factor independent of CAG repeat length influences age at onset of Machado-Joseph disease.

Authors:  A L DeStefano; L A Cupples; P Maciel; C Gaspar; J Radvany; D M Dawson; L Sudarsky; L Corwin; P Coutinho; P MacLeod
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

6.  Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias.

Authors:  Heike Jacobi; Sophie Tezenas du Montcel; Peter Bauer; Paola Giunti; Arron Cook; Robyn Labrum; Michael H Parkinson; Alexandra Durr; Alexis Brice; Perrine Charles; Cecilia Marelli; Caterina Mariotti; Lorenzo Nanetti; Lidia Sarro; Maria Rakowicz; Anna Sulek; Anna Sobanska; Tanja Schmitz-Hübsch; Ludger Schöls; Holger Hengel; Laszlo Baliko; Bela Melegh; Alessandro Filla; Antonella Antenora; Jon Infante; José Berciano; Bart P van de Warrenburg; Dagmar Timmann; Sandra Szymanski; Sylvia Boesch; Wolfgang Nachbauer; Jun-Suk Kang; Massimo Pandolfo; Jörg B Schulz; Audrey Tanguy Melac; Alhassane Diallo; Thomas Klockgether
Journal:  J Neurol       Date:  2018-06-29       Impact factor: 4.849

7.  Different origins of mutations at the Machado-Joseph locus (MJD1)

Authors:  P Iughetti; M Zatz; M R Bueno; S K Marie
Journal:  J Med Genet       Date:  1996-05       Impact factor: 6.318

8.  Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line.

Authors:  Lauren R Moore; Laura Keller; David D Bushart; Rodrigo G Delatorre; Duojia Li; Hayley S McLoughlin; Maria do Carmo Costa; Vikram G Shakkottai; Gary D Smith; Henry L Paulson
Journal:  Stem Cell Res       Date:  2019-07-16       Impact factor: 2.020

9.  Relations between genotype and phenotype in German patients with the Machado-Joseph disease mutation.

Authors:  L Schöls; G Amoiridis; J T Epplen; M Langkafel; H Przuntek; O Riess
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

10.  Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.

Authors:  Hayley S McLoughlin; Lauren R Moore; Ravi Chopra; Robert Komlo; Megan McKenzie; Kate G Blumenstein; Hien Zhao; Holly B Kordasiewicz; Vikram G Shakkottai; Henry L Paulson
Journal:  Ann Neurol       Date:  2018-08-06       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.